Front. Endocrinol. Frontiers in Endocrinology Front. Endocrinol. 1664-2392 Frontiers Media S.A. 10.3389/fendo.2023.1093257 Endocrinology Review Obesity and endocrine-related cancer: The important role of IGF-1 Zhong Wentao Wang Xueqing Wang Yufei Sun Guoqian Zhang Jia Li Zhuo * Department of Endocrinology and Metabolism, First Hospital of Jilin University, Changchun, Jilin, China

Edited by: Michaela Ruth Reagan, MaineHealth, United States

Reviewed by: Paola Maroni, Ospedale Galeazzi S.p.A, Italy; Silvio Naviglio, University of Campania Luigi Vanvitelli, Italy

*Correspondence: Zhuo Li, zhuoli@jlu.edu.cn

This article was submitted to Obesity, a section of the journal Frontiers in Endocrinology

 23 01 2023 2023 14 1093257 08 11 2022 04 01 2023 Copyright © 2023 Zhong, Wang, Wang, Sun, Zhang and Li 2023 Zhong, Wang, Wang, Sun, Zhang and Li

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Obesity is increasingly becoming a global epidemic of concern and is considered a risk factor for several endocrine-related cancers. Moreover, obesity is associated with cancer development and poor prognosis. As a metabolic abnormality, obesity leads to a series of changes in insulin, IGF-1, sex hormones, IGFBPs, and adipokines. Among these factors, IGF-1 plays an important role in obesity-related endocrine cancers. This review describes the role of obesity in endocrine-related cancers, such as prostate cancer, breast cancer and pancreatic cancer, focusing on the mechanism of IGF-1 and the crosstalk with estrogen and adipokines. In addition, this review briefly introduces the current status of IGF-1R inhibitors in clinical practice and shows the prospect of IGF-1R inhibitors in combination with other anticancer drugs.

 obesity endocrine-related cancer insulin-like growth factor-1(IGF-1R) insulin like growth factor-1 receptor (IGF-1R) mechanism 82070871 National Natural Science Foundation of China10.13039/501100001809 1 Introduction

Obesity is a risk factor for several chronic diseases, such as hypertension, type 2 diabetes, dyslipidemia and cardiovascular disease. Epidemiological studies have shown that obesity is also a risk factor for certain types of cancer, such as postmenopausal breast cancer, prostate cancer, endometrial cancer, pancreatic cancer and thyroid cancer. Furthermore, a growing number of studies indicate that obesity predicts unfavorable outcomes for cancers (1). Obesity, a clinical marker of insulin resistance and metabolic syndrome, is associated with multiple biological metabolic changes, such as hyperinsulinemia, an increase in free fatty acid levels and triglycerides and hypoHDL-cholesterol. Hyperinsulinemia induces a decrease in insulin-like growth factor binding protein-1 and 2 (IGFBP-1 and 2) and reduces sex hormone binding globulin (SHBG) levels, resulting in an increase in free estrogen and androgen and insulin-like growth factor-1 (IGF-1) levels (2). The IGF system plays an important role in normal growth and development as well as in a variety of pathological situations, particularly tumorigenesis. Obesity is associated with an increased incidence of cancers arising from tissues responsive to estrogenic stimulation, including the endometrium, breast, and prostate (3). In postmenopausal women, elevated bioavailable plasma estrogen levels are related to an increased risk of breast cancer and endometrial cancer (4). Sex steroid alterations are associated with prostate cancer development and progression. This review will focus on the effects of IGF-1 on the relationships between obesity and endocrine-related cancer, especially on prostate cancer, breast cancer and pancreatic cancer.

 2 Insulin-like growth factor-1

Insulin-like growth factors (IGFs) were first described in the late 1950s as skeletal growth factors produced in the liver in response to pituitary growth hormone (GH), and these growth factors play a fundamental role in regulating somatic growth according to nutritional conditions. IGFs, a group of polypeptide substances with growth-promoting effects, consist of IGF-1 and IGF-2. IGF-1 is produced in the liver, secreted into the circulation and acts in target tissues. In addition to the liver, IGF-1 is also produced in most extrahepatic tissues and functions as an endocrine, autocrine and paracrine growth stimulator to regulate cell growth (5). IGF-1 is a major target gene of growth hormone, and its product mediates many of the actions of growth hormone on growth and development. IGF action is also important in the development of specific organs, such as in the nervous system, in which IGF signaling regulates neuronal proliferation, apoptosis and cell survival. However, the IGF system has been implicated in various pathophysiological conditions and plays a particularly prominent role in the development and progression of human cancer (6). A growing body of epidemiological data suggests that high levels of circulating IGF-1 constitute a risk factor for the development of breast, prostate, colon, and lung cancer.

IGF-1 receptor (IGF-1R) is not mutated in most cancers and has a high degree of structural homology with insulin receptor (INSR), particularly in the tyrosine domain, which can form a heterodimer with each other and signal through many common mediators, but the two receptor signaling axes exhibit marked functional variance (7, 8). In addition, the expression levels of IGF-1R and INSR are predictive of cancer outcome. Experimentally, the modulation of IGF-1R activity affects the growth of many types of tumor cells. As a result of these findings, intensive effort is being directed toward investigating the utility of the IGF system as both a diagnostic marker and a therapeutic target in cancer therapy (6).

Six high-affinity IGF-binding proteins (IGFBP) are described at present. They are synthesized by several cell types, mostly from the fibroblast lineage, which regulate IGF-1 and IGF-2. In this family, IGFBP-3 is the most abundant IGFBP in blood, and IGFBP-2 is the second most abundant IGFBP. The IGF-1-IGFBP-3 complex and IGF1-IGFBP-5 complex bind to a third protein termed the acid labile subunit (9, 10). IGFBP-4, 5 and 6 are present in lower concentrations and appear to be less important for the regulation of free IGF concentrations in serum (5). More than 99% IGF-1 is bound to IGFBPs, which can increase the half-life of IGF to some extent, and their binding affinity for IGF is nearly 10 times higher than that for IGF-1R (10, 11). Therefore, the function and concentration of IGFBPs are critical to regulate the biological actions of IGFs.

 3 Endocrine-related cancer

Circulating insulin and IGF-1 increase in the obese state, and sex hormones, adipokines and other inflammatory factors also vary (12). Both IGF and insulin can increase the expression of IGF-1R and INSR, which forms a functional network of interactions. In addition, IGFBPs are produced at lower levels, which reduces their inhibitory effects on insulin/IGF. IGF-1 has been studied more frequently in prostate cancer. In addition to IGF-1, estrogen is critical in breast cancer, and adiponectin is receiving increasing attention in pancreatic cancer; leptin and adiponectin have been relatively less studied in endocrine-related cancers. To varying degrees, these biological factors play a role in endocrine-related cancers.

3.1 Prostate cancer

A correlation between obesity and prostate cancer risk has been reported in a number of studies, especially in abdominal obesity, with a linear relationship between increasing BMI and prostate cancer (13). Moreover, obesity is associated with an increased risk of recurrence after treatment, advanced cancer progression and prostate cancer-specific mortality for prostate cancer patients (14, 15) Obesity and chronic hyperinsulinemia are known to reduce the production of IGFBPs and increase IGF-1 biological activity (16). The insulin/IGF-1 axis is associated with obesity-induced prostate carcinogenesis via the phosphatidylinostitol-3 kinase (PI3K)/Akt/mTOR pathways. Using Hi-Myc/HIT mice, Wang et al. showed that IGF-1 promotes prostate cancer and that the IGF-1/AKT/FOXO3A/BIM pathway plays an important role (17). Prostate cancer cells overexpress IGF-1R and INSR (18). In vitro and in vivo experiments suggest that both IGF-1R and INSR promote angiogenesis in prostate cancer (19). Sayeed et al. showed that IGF-IR signaling strictly regulates prosurvival signaling in prostate cancer by controlling the expression of a5b1 integrin, which indicates that IGF-1R and INSR promote the growth and invasion of prostate cancer (20). Therefore, changes in IGFS in obese people may increase the potential risk of prostate cancer.

According to a recent study by Markers et al., the serum levels of steroid hormones were not associated with prostate cancer risk in obese men, which is consistent with most previous studies (21). However, many studies have indicated that low testosterone and elevated estrogen levels in obese men are correlated with the development of prostate cancer (22). To clarify these contradictory results, further investigation of the underlying mechanisms is still needed. Leptin has prostate cancer-promoting effects and is positively correlated with fat mass, while adiponectin has anticancer effects and is negatively correlated with BMI (23, 24). The ratio between leptin and adiponectin is imbalanced in obese individuals, leading to abnormalities in the AMPK and mTOR signaling pathways, which may influence prostate cancer development (25). In addition, adipose tissue itself is also associated with prostate cancer. Periprostatic adipose tissue secretes a variety of inflammatory factors and creates a tumor microenvironment that promotes the development of prostate cancer (26–29).

 3.2 Breast cancer

Obesity is associated with the occurrence and progression of breast cancer, especially postmenopausal ER+/PR+ breast cancer (30, 31). According to a systematic evaluation, higher levels of IGF-1, IGFBP-3 and leptin and lower levels of adiponectin among obesity-associated protein biomarkers are correlated with an increased breast cancer risk (32). The association between IGFBP-3 and breast cancer risk is reportedly due to its interaction with IGF-1, and this interaction can be eliminated by the adjustment of IGF-1, suggesting that IGF-1 itself is an inducing factor of breast cancer (33).

In addition to the direct regulation of estrogen and these obesity-associated protein biomarkers on breast cancer cells, these biological factors exhibit crosstalk. The role of IGF-1 is mediated by IGF-1R, which is overexpressed in breast cancer (34, 35). IGF-1R promotes breast cancer by altering the expression of proliferation and survival genes through the Ras/Raf/MAPK and PI3K/Akt signaling pathways (36, 37). Insulin can also promote breast cancer via these signaling pathways (38). The estrogen-induced production of ROS leads to DNA damage, while estrogen itself inhibits the DNA damage response and can promote cell proliferation, which is the background of estrogen-induced breast cancer (39–41). Postmenopausal adipose tissue is an important site of estrogen production. The rate of estrogen conversion is higher in obese postmenopausal women, and obesity increases estrogen levels in ER receptor-positive breast cancer tissue, which increases the risk associated with breast cancer (42, 43). This risk is further increased by a reduction in SHBG in the liver of individuals with obesity and an increase in the concentration of non-SHBG-bound estradiol (E2, the most abundant and active estrogen) (44, 45). Similar to IGF-1, estrogen can also play a role in breast cancer through the MAPK and PI3K/Akt signaling pathways, and estrogen and IGF-1 exhibit crosstalk. E2 accelerates and enhances the binding of ERα to IGF-1R, and ERα, activated by the Ras-MAPK cascade of the growth factor signaling pathway, induces the phosphorylation of Akt and ERK1/2 after rapid binding to IGF-1R, thereby enlarging IGF-1R signaling (46). Leptin, which is associated with estrogen, also contributes to breast cancer. It may upregulate the PI3K/Akt pathway, MAPK pathway and STAT3 pathway, the downstream signaling pathways of Ob-R, which stimulate oncogenesis (47). Interestingly, elevated cAMP may inhibit leptin-induced migration of highly aggressive breast cancer cells MDA-MB-231 by suppressing ERK1/2 and STAT3 signaling pathway (48, 49). Leptin also promotes the proliferation of breast cancer cells by activating the Wnt/β-catenin pathway (50). Aromatase is the rate-limiting enzyme for estrogen synthesis, and leptin can induce aromatase expression through COX-2 expression in breast cancer cells and increase estrogen synthesis, promoting the progression of breast cancer (51, 52). Zahid et al. showed that the increase in aromatase expression in the obese state may be mediated by leptin via the P53-HIF1α/PKM2-aromatase axis (53). In addition, Morad et al. suggested that estrogen can in turn increase the expression of leptin and leptin receptors (54). In ERα-negative breast cancer, adiponectin inhibited IGF-1-induced cell migration, whereas in ERα-positive breast cancer, low concentrations of adiponectin promoted IGF-1R phosphorylation and thus enhanced IGF-1/IGF-1R signaling (55, 56). The concentration of adiponectin tends to decrease in obese states, which may reduce the protective effect and increase the risk of breast cancer. In conclusion, in obese women, especially postmenopausal women, the role of estrogen and obesity-associated protein biomarkers in breast cancer is complicated due to their own changes and crosstalk.

 3.3 Pancreatic cancer

Epidemiological surveys show that obesity is associated with pancreatic cancer morbidity and mortality, and the morbidity of pancreatic cancer increases with increasing BMI (57, 58). Since approximately 90% of pancreatic cancers are pancreatic ductal carcinoma (PDAC), many models have been built with PDAC. Various events are considered to elevate the risk of pancreatic cancer in obesity, such as the increase in IGF-1. A survey including 105 patients showed that IGF-1R was overexpressed in more than half of the PDAC samples (59). Du et al. indicated that high IGF-1R expression was associated with shorter overall survival and relapse in patients (60). In PDAC, both insulin and IGF-1 are considered to play a role in cancer development and progression, with the PI3K and MAPK signaling pathways as its central pathways, and these signals are enhanced in obesity (61, 62). Tian et al. inhibited the PI3K/Akt signaling pathway by knocking down the IGF-1R gene, thereby inhibiting the proliferation of pancreatic cancer cells and increasing the sensitivity of anticancer drugs, which to some extent proves the role of IGF-1 in pancreatic cancer (63). Oncogenic KRAS mutation occurs in approximately 90% of PDAC, and MEK/ERK is one of the main effector pathways of KRAS signaling (64). MEK/ERK-stimulated IGF-1R signaling is required for murine pancreatic epithelial cell transformation, which suggests a critical role for IGF-1R signaling in pancreatic carcinogenesis (65). In addition, leptin, adiponectin and inflammatory factors also play an important role in the association between obesity and pancreatic cancer (66, 67). Adiponectin acts by binding to AdipoRs to activate downstream signaling pathways and AdipoRon is a synthetic small molecule AdipoR agonist that binds to the AdipoR1 and AdipoR2. AdipoRon induces pancreatic cancer cell death by activating ERK1/2, however, obesity weakens this anti-cancer effect (68, 69). Messaggio et al. demonstrated that leptin promotes pancreatic tumor growth through altered pathways of STAT3 and PI3K/AKT signaling, whereas AdipoRon inhibits leptin-induced STAT3 activation and pancreatic tumor growth in vivo ( 70, 71). Recently, Ragone et al. combined gemcitabine, a first-line agent for pancreatic cancer, with AdipoRon to enhance growth inhibition in human PDAC cell lines, which may be associated with the AdipoRon mediated p44/42 MAPK(ERK1/2) pathway (72).

 3.4 Other endocrine-related cancers

Ovarian, endometrial and thyroid cancers are also associated with obesity. In ovarian cancer, epidemiological studies show that obesity may promote the peritoneal dissemination of ovarian cancer and increase patient mortality (73, 74). Ignacio et al. suggest that obesity may accelerate the peritoneal dissemination of ovarian cancer by producing more proinflammatory chemokines and recruiting macrophages (75). Leptin helps maintain the cancer stem cell-like properties of ovarian cancer cells and stimulates the migration and invasion of ovarian cancer cells (76). IGF-IR mediates TGFβ for the maintenance of EMT transformation, angiogenesis and extracellular matrix remodeling (77). Together, these factors contribute to the development of ovarian cancer. In endometrial cancer, epidemiological studies have shown that obesity is associated with an increased incidence of endometrial cancer and is correlated with recurrence and death in patients with endometrial cancer (78). Merritt et al. indicated that estrogen, insulin, and IGF-1 are associated with the multistage process of endometrial carcinogenesis (79). Estrogen can stimulate cell proliferation by increasing IGF-1 synthesis and IGF-IR expression in the uterus via ERα (80). In addition, in the absence of IGFBP-1 synthesis in obesity, IGF-1 may further induce the abnormal proliferation of endometrial cells, which is a possible pathway for endometrial cancer formation (81). In thyroid cancer, a cohort study collected more than 450,000 samples from 1995 to 2015 and suggested that being overweight and obesity may be important causes of the increased incidence of thyroid cancer (82). IGF-1 may play a role in the association between obesity and thyroid cancer (83). IGF-1 is positively associated with the risk of developing thyroid cancer (84). Yang et al. suggested that IGF-1 promotes the proliferation and invasion of thyroid-like carcinoma through the STAT3 pathway (85). Studies have also indicated a role for the IGF axis in thyroid tumorigenesis (86).

 4 Therapies targeting the IGF family

In the face of increasing cancer incidence, researchers have targeted the IGF axis for therapeutic intervention due to its role in cancer.Three main approaches are used to target IGFs, including IGF-1R monoclonal antibodies, IGF-1R tyrosine kinase inhibitors (TKIs) and IGF-1/-2 blocking monoclonal antibodies. IGF-1R monoclonal antibodies (IGF-1R mAb, such as cixutumumab, figitumumab and ganitumab) function mainly by blocking ligand-receptor action, inducing the internalization/degradation of IGF-1R and partially downregulating IGF-1R/INSR hybrid receptors (87, 88). Among IGF-1R TKIs, ATP-competitive TKIs act by competing for the binding site of the IGF-1R kinase domain to ATP, which inhibits both IGF-1R and INSR. However, non-ATP competitive IGF-1R inhibitors do not influence INSR (89, 90). IGF-1/-2 blocking mAb blocks IGF-1R and INSR-A and their hybrid receptors from transducing proliferative/anti-apoptotic signals by binding IGF-1 and IGF-2 without affecting INSR-B and insulin function (91). For more than a decade, researchers have conducted numerous clinical trials on these three classes of inhibitors due to the role of IGF-1 in tumor development ( Table 1 ). Unfortunately, the results of most clinical trials targeting single-agent activity were disappointing. Some IGF-1R inhibitors have been discontinued or abandoned from development; for example, Pfizer decided to discontinue figitumumab (CP-751871) in 2010, and Roche shifted to teprotumumab to treat ophthalmic disease.

Clinical trials of IGF-1 inhibitors as single agents.

Cancer type Drug Drug Type Clinical trial Phase Number of patiens Response Trial ID Ref.
Postmenopausal women with hormone receptor–positive breast cancer Cixutumumab Anti-IGF-1R mAb II n=93(31 in the cixutumumab alone group) No significant clinical effect observed with cixutumumab alone NCT00728949 (92)
Advanced hepatocellular carcinoma Cixutumumab Anti-IGF-1R mAb II Qnly stage 1 was accrued: n= 24 No significant clinical effect NCT00639509 (93)
Refractory Solid Tumors Cixutumumab Anti-IGF-1R mAb II n=116 Limited objective single-agent activity of cixutumumab was observed;PR:20%(neuroblastoma with only MIBG evaluable disease ), SD:15%(patients with a variety of solid tumor types) NCT00831844 (94)
Recurrent or refractory TETs Cixutumumab Anti-IGF-1R mAb II n=49(37 thymomas;12 thymic carcinomas) PR :14%,SD :76%(thymoma cohort);PR:0,SD:42%(thymic carcinoma cohort) NCT00965250 (95)
Rhabdomyosar-coma; Leiomyosarcoma; Adipocytic sarcoma;Synovial sarcoma; Ewing family of tumours (including ES-1 and peripheral neuroectodermal tumour) Cixutumumab Anti-IGF-1R mAb II n=113(all tiers except adipocytic sarcoma were closed after stage 1 due to futility)  PFR:12%(rhabdomyosarcoma, n = 17), 14%( leiomyosarcoma, n=22), 32%(adipocytic sarcoma, n=37), 18%(synovial sarcoma, n=17), 11%(Ewing family of tumours, n=18) NCT00668148 (96)
Ewing sarcoma, osteosarcoma and other sarcomas Figitumumab Anti-IGF-1R mAb I/II Phase Iportion n=31, phase II portion n=107 phaseIIportion ORR=14.2% NCT00560235 (97)
Neuroendocrine tumor MK-0646 Anti-IGF-1R mAb II n=25 inactive as a single agent NCT00610129 (98)
Previously treated, locally advanced or metastatic NSCLC of the SCC or AC subtypes AXL1717 IGF-1R TKI II n=99(58 in the AXL1717 group) 12-week PFS: 25.9%(AXL1717 group), 39.0%(docetaxel group),without any statistically significant differences NCT01561456 (99)
Adrenocortical carcinoma Linsitinib IGF-1R/INSR TKI III n=135 No difference in overall survival was noted between linsitinib and placebo NCT00924989 (100)
Metastatic castrate resistant prostate cancer Linsitinib IGF-1R/INSR TKI II n=18 No significant PSA or objective response;without any effect on circulating tumor cells or survival benefit NCT01533246 (101)
advanced/metastatic solid cancers Xentuzumab IGF-1/IGF-2-neutralizing Ab I Study 1280.1:n=61; Study 1280.2:n=64 Preliminary anti-tumour activity;Study 1280.1 part 1:PR(n=2),SD(n=3);Study 1280.1 part2:SD(n=3);Study 1280.2: no objective responses;SD(n=2 in part1) NCT01403974; NCT01317420 (102)
advanced solid tumors xentuzumab IGF-1/IGF-2-neutralizing Ab I n=21 Preliminary anti-tumour activity;ORR=9.5%SD=19.0% NCT02145741 (103)

IGF-1R, insulin-like growth factor receptor 1; INSR, insulin receptor; PR, partial response; SD, stable disease; ORR, objective response rate; AE, most common grade 3-4 adverse events; MIBG, meta-iodo-benzyl-guanidine; PFR, progression-free survival rate; TETs, thymic epithelial tumors; TKI, tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer; SCC, squamous cell carcinoma; AC, adenocarcinoma; PFS, progression-free survival.

One possible reason for the resistance of cancer cells to IGF-1R inhibitors is the compensatory activation of RTK signaling; therefore, several combination therapies have recently emerged to improve efficacy (104, 105), such as IGF-1R inhibitors in combination with other RTK inhibitors. EGFR is an important factor in the RTK signaling pathway, and the IGF-1/2 neutralizing antibody m708.5 exhibits a strong synergistic effect with gefitinib, which shows benefit in the treatment of neuroblastoma and breast cancer (106). IGF-1R inhibitors are valuable in endocrine-related tumors. For example, the activation of the IGF-1R pathway is associated with tamoxifen resistance, while the elimination of IGF-1R signaling with linsitinib could restore the sensitivity of endocrine therapy (107). Combined IGF-1R/mTOR inhibition also shows synergistic effects. In ACC, in vitro assays showed stronger antiproliferative activity in combination with sirolimus or everolimus than with linsitinib (108). A phase I clinical trial of ridaforolimus in combination with anti-IGF1R mAb dalozumab also demonstrated clinical activity in advanced cancer (109). Some experimental support also exists for the combination of IGF-1R inhibitors with therapeutic approaches to induce DNA damage. Most invasive breast cancers have insulin/IGF-1R signaling activation, and xentuzumab in combination with paclitaxel can effectively reduce metastasis incidence and metastatic burden in preclinical mouse models (110). IGF-1R is also involved in radiotherapy resistance. Low IGF-1R expression was demonstrated to increase the sensitivity of CRC to radiation therapy when treated with NVP-ADW742 in CRC cells (111, 112). Some anticancer drugs containing IGF-1R inhibitors have entered in phase III clinical trials, but clinical benefit is not significant. More clinical trials are needed to prove the effectiveness of the combination therapy.

 5 Conclusion

Obesity has been called the disease of modern civilization and is a heavy disease burden for society. Disorders of insulin, IGF-1, sex hormones, adipokines and inflammatory factors have been observed in numerous studies in the presence of obesity. Obesity is also recognized as a factor associated with cancer, and adipose tissue, which is an active endocrine organ, strengthens the link between obesity and endocrine-related cancers. IGF-1 plays an important role in obesity-associated endocrine-related cancers, promoting cancer development mainly through the PI3K/AKT and MAPK pathways. Insulin, IGF-1, sex hormones and adipokines also exhibit crosstalk to synergistically function in this process. The relationships among them and their roles are shown in Figure 1 . Investigators have conducted a series of clinical trials targeting IGFs; however, most of them failed to demonstrate single-agent efficacy. Although drug combinations perform better in preclinical studies, fewer patients benefit from clinical trials. The following issues remain in the study of obesity and endocrine-related cancers: 1. the mechanism of action of obesity-related biologic factors in cancer and the crosstalk among them still need to be studied further; 2. whether obesity-related biologic factors can be used as biomarkers to evaluate endocrine-related cancers has not been fully investigated; 3. suitable predictive biomarkers urgently need to be identified in clinical trials to design reasonable joint therapeutic strategies accordingly. If these problems are solved in the future, IGF inhibitors can play a larger role in clinical practice and provide more treatment options for cancer patients.

Relationships and roles in endocrine-related cancer. cAMP, cyclic adenosine monophosphate; ObR, leptin receptor; STAT3, signal transducer and activator of transcription 3; FOXO3a, Forkhead box O3; IGF-1, insulin-like growth factor; IGF-1R, insulin-like growth factor receptor 1; P13K/Akt, phosphatidylinositol 3-kinase/protein kinase B; ERα, estrogen receptor α; MAPK,mitogen-activated protein kinase;MEK,mitogen-activated protein kinase;ERK, extractor signal regulated kinase.

 Author contributions

WZ wrote and revised the manuscript. ZL wrote the outline and critically revised the manuscript. WZ, XW, YW, GS and JZ contributed to literature search. WZ and XW prepared the table and figure. All authors have read and given approval of the final manuscript.

 Funding

This study was supported by the National Natural Science Foundation of China (82070871).

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Sung H Siegel RL Torre LA Pearson-Stuttard J Islami F Fedewa SA . Global patterns in excess body weight and the associated cancer burden. CA: Cancer J Clin (2019) 69(2):88–112. doi: 10.3322/caac.21499 Amin MN Hussain MS Sarwar MS Rahman Moghal MM Das A Hossain MZ . How the association between obesity and inflammation may lead to insulin resistance and cancer. Diabetes Metab Syndr (2019) 13(2):1213–24. doi: 10.1016/j.dsx.2019.01.041 Crujeiras AB Casanueva FF . Obesity and the reproductive system disorders: Epigenetics as a potential bridge. Hum Reprod Update (2015) 21(2):249–61. doi: 10.1093/humupd/dmu060 Zhao H Zhou L Shangguan AJ Bulun SE . Aromatase expression and regulation in breast and endometrial cancer. J Mol Endocrinol (2016) 57(1):R19–33. doi: 10.1530/JME-15-0310 Clemmons DR . Modifying Igf1 activity: An approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discovery (2007) 6(10):821–33. doi: 10.1038/nrd2359 Cao J Yee D . Disrupting insulin and igf receptor function in cancer. Int J Mol Sci (2021) 22(2):555. doi: 10.3390/ijms22020555 Maki RG . Small is beautiful: Insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol (2010) 28(33):4985–95. doi: 10.1200/JCO.2009.27.5040 Osher E Macaulay VM . Therapeutic targeting of the igf axis. Cells (2019) 8(8):895. doi: 10.3390/cells8080895 Cai Q Dozmorov M Oh Y . Igfbp-3/Igfbp-3 receptor system as an anti-tumor and anti-metastatic signaling in cancer. Cells (2020) 9(5):1261. doi: 10.3390/cells9051261 Bach LA . Igf-binding proteins. J Mol Endocrinol (2018) 61(1):T11–28. doi: 10.1530/JME-17-0254 Fettig LM Yee D . Advances in insulin-like growth factor biology and -directed cancer therapeutics. Adv Cancer Res (2020) 147:229–57. doi: 10.1016/bs.acr.2020.04.005 Nimptsch K Konigorski S Pischon T . Diagnosis of obesity and use of obesity biomarkers in science and clinical medicine. Metabolism (2019) 92:61–70. doi: 10.1016/j.metabol.2018.12.006 Choi JB Myong JP Lee Y Kim I Kim JH Hong SH . Does increased body mass index lead to elevated prostate cancer risk? it depends on waist circumference. BMC Cancer (2020) 20(1):589. doi: 10.1186/s12885-020-07089-5 Freedland SJ Branche BL Howard LE Hamilton RJ Aronson WJ Terris MK . Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: Results from the search database. BJU Int (2019) 124(1):69–75. doi: 10.1111/bju.14594 Genkinger JM Wu K Wang M Albanes D Black A van den Brandt PA . Measures of body fatness and height in early and mid-to-Late adulthood and prostate cancer: Risk and mortality in the pooling project of prospective studies of diet and cancer. Ann Oncol (2020) 31(1):103–14. doi: 10.1016/j.annonc.2019.09.007 Uehara H Kobayashi T Matsumoto M Watanabe S Yoneda A Bando Y . Adipose Tissue:Critical contributor to the development of prostate cancer. J Med Invest (2018) 65(1.2):9–17. doi: 10.2152/jmi.65.9 Wang S Wang N Yu B Cao M Wang Y Guo Y . Circulating igf-1 promotes prostate adenocarcinoma Via Foxo3a/Bim signaling in a double-transgenic mouse model. Oncogene (2019) 38(36):6338–53. doi: 10.1038/s41388-019-0880-9 Breen KJ O'Neill A Murphy L Fan Y Boyce S Fitzgerald N . Investigating the role of the igf axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery. Prostate (2017) 77(12):1288–300. doi: 10.1002/pros.23389 Heidegger I Kern J Ofer P Klocker H Massoner P . Oncogenic functions of Igf1r and insr in prostate cancer include enhanced tumor growth, cell migration and angiogenesis. Oncotarget (2014) 5(9):2723–35. doi: 10.18632/oncotarget.1884 Sayeed A Fedele C Trerotola M Ganguly KK Languino LR . Igf-ir promotes prostate cancer growth by stabilizing Alpha5beta1 integrin protein levels. PloS One (2013) 8(10):e76513. doi: 10.1371/journal.pone.0076513 Chau CH Till C Price DK Goodman PJ Neuhouser ML Pollak MN . Serum markers, obesity and prostate cancer risk: Results from the prostate cancer prevention trial. Endocr Relat Cancer (2022) 29(2):99–109. doi: 10.1530/ERC-21-0107 Allott EH Masko EM Freedland SJ . Obesity and prostate cancer: Weighing the evidence. Eur Urol (2013) 63(5):800–9. doi: 10.1016/j.eururo.2012.11.013 Kamel HFM Nassir AM Al Refai AA . Assessment of expression levels of leptin and leptin receptor as potential biomarkers for risk of prostate cancer development and aggressiveness. Cancer Med (2020) 9(15):5687–96. doi: 10.1002/cam4.3082 Yoon YS Kwon AR Lee YK Oh SW . Circulating adipokines and risk of obesity related cancers: A systematic review and meta-analysis. Obes Res Clin Pract (2019) 13(4):329–39. doi: 10.1016/j.orcp.2019.03.006 Hu X Hu C Zhang C Zhang M Long S Cao Z . Role of adiponectin in prostate cancer. Int Braz J Urol (2019) 45(2):220–8. doi: 10.1590/S1677-5538.IBJU.2018.0261 La Civita E Liotti A Cennamo M Crocetto F Ferro M Liguoro P . Peri-prostatic adipocyte-released tgfbeta enhances prostate cancer cell motility by upregulation of connective tissue growth factor. Biomedicines (2021) 9(11):1692. doi: 10.3390/biomedicines9111692 Mangiola S Stuchbery R Macintyre G Clarkson MJ Peters JS Costello AJ . Periprostatic fat tissue transcriptome reveals a signature diagnostic for high-risk prostate cancer. Endocr Relat Cancer (2018) 25(5):569–81. doi: 10.1530/ERC-18-0058 Nassar ZD Aref AT Miladinovic D Mah CY Raj GV Hoy AJ . Peri-prostatic adipose tissue: The metabolic microenvironment of prostate cancer. BJU Int (2018) 121(S3):9–21. doi: 10.1111/bju.14173 Gucalp A Iyengar NM Zhou XK Giri DD Falcone DJ Wang H . Periprostatic adipose inflammation is associated with high-grade prostate cancer. Prostate Cancer Prostatic Dis (2017) 20(4):418–23. doi: 10.1038/pcan.2017.31 Neuhouser ML Aragaki AK Prentice RL Manson JE Chlebowski R Carty CL . Overweight, obesity, and postmenopausal invasive breast cancer risk: A secondary analysis of the women's health initiative randomized clinical trials. JAMA Oncol (2015) 1(5):611–21. doi: 10.1001/jamaoncol.2015.1546 Chan DSM Vieira AR Aune D Bandera EV Greenwood DC McTiernan A . Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol (2014) 25(10):1901–14. doi: 10.1093/annonc/mdu042 Wu X Zhang X Hao Y Li J . Obesity-related protein biomarkers for predicting breast cancer risk: An overview of systematic reviews. Breast Cancer (2021) 28(1):25–39. doi: 10.1007/s12282-020-01182-0 Endogenous H Breast Cancer Collaborative G Key TJ Appleby PN Reeves GK Roddam AW . Insulin-like growth factor 1 (Igf1), igf binding protein 3 (Igfbp3), and breast cancer risk: Pooled individual data analysis of 17 prospective studies. Lancet Oncol (2010) 11(6):530–42. doi: 10.1016/S1470-2045(10)70095-4 Silva Rocha F da Silva Maues JH Brito Lins Pereira CM Moreira-Nunes CA Rodriguez Burbano RM . Analysis of increased egfr and igf-1r signaling and its correlation with socio-epidemiological features and biological profile in breast cancer patients: A study in northern Brazil. Breast Cancer (Dove Med Press) (2021) 13:325–39. doi: 10.2147/BCTT.S308554 Yerushalmi R Gelmon KA Leung S Gao D Cheang M Pollak M . Insulin-like growth factor receptor (Igf-1r) in breast cancer subtypes. Breast Cancer Res Treat (2012) 132(1):131–42. doi: 10.1007/s10549-011-1529-8 Bowers LW Cavazos DA Maximo IX Brenner AJ Hursting SD deGraffenried LA . Obesity enhances nongenomic estrogen receptor crosstalk with the Pi3k/Akt and mapk pathways to promote in vitro measures of breast cancer progression. Breast Cancer Res (2013) 15(4):R59. doi: 10.1186/bcr3453 Zhang X Lin M van Golen KL Yoshioka K Itoh K Yee D . Multiple signaling pathways are activated during insulin-like growth factor-I (Igf-I) stimulated breast cancer cell migration. Breast Cancer Res Treat (2005) 93(2):159–68. doi: 10.1007/s10549-005-4626-8 Yee LD Mortimer JE Natarajan R Dietze EC Seewaldt VL . Metabolic health, insulin, and breast cancer: Why oncologists should care about insulin. Front Endocrinol (Lausanne) (2020) 11:58. doi: 10.3389/fendo.2020.00058 Zhang S Shang P Gao K Zhao G Zhou J Chen R . Dynamics of estrogen-induced ros and DNA strand break generation in estrogen receptor alpha-positive breast cancer. Biochem Biophys Res Commun (2022) 602:170–8. doi: 10.1016/j.bbrc.2022.02.089 Rajan A Nadhan R Latha NR Krishnan N Warrier AV Srinivas P . Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis. Biochim Biophys Acta Rev Cancer (2021) 1875(1):188482. doi: 10.1016/j.bbcan.2020.188482 Wu CH Chuang HY Wang CL Hsu CY Long CY Hsieh TH . Estradiol induces cell proliferation in Mcf7 mammospheres through Her2/Cox2. Mol Med Rep (2019) 19(3):2341–9. doi: 10.3892/mmr.2019.9879 Kakugawa Y Tada H Kawai M Suzuki T Nishino Y Kanemura S . Associations of obesity and physical activity with serum and intratumoral sex steroid hormone levels among postmenopausal women with breast cancer: Analysis of paired serum and tumor tissue samples. Breast Cancer Res Treat (2017) 162(1):115–25. doi: 10.1007/s10549-016-4094-3 Hetemaki N Savolainen-Peltonen H Tikkanen MJ Wang F Paatela H Hamalainen E . Estrogen metabolism in abdominal subcutaneous and visceral adipose tissue in postmenopausal women. J Clin Endocrinol Metab (2017) 102(12):4588–95. doi: 10.1210/jc.2017-01474 Lipworth L Adami HO Trichopoulos D Carlstrom K Mantzoros C . Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer. Epidemiology (1996) 7(1):96–100. doi: 10.1097/00001648-199601000-00017 Grasa MDM Gulfo J Camps N Alcala R Monserrat L Moreno-Navarrete JM . Modulation of shbg binding to testosterone and estradiol by sex and morbid obesity. Eur J Endocrinol (2017) 176(4):393–404. doi: 10.1530/EJE-16-0834 Yu Z Gao W Jiang E Lu F Zhang L Shi Z . Interaction between igf-ir and er induced by E2 and igf-I. PloS One (2013) 8(5):e62642. doi: 10.1371/journal.pone.0062642 Schmidt S Monk JM Robinson LE Mourtzakis M . The integrative role of leptin, oestrogen and the insulin family in obesity-associated breast cancer: Potential effects of exercise. Obes Rev (2015) 16(6):473–87. doi: 10.1111/obr.12281 Naviglio S Di Gesto D Romano M Sorrentino A Illiano F Sorvillo L . Leptin enhances growth inhibition by camp elevating agents through apoptosis of mda-Mb-231 breast cancer cells. Cancer Biol Ther (2009) 8(12):1183–90. doi: 10.4161/cbt.8.12.8562 Naviglio S Di Gesto D Illiano F Chiosi E Giordano A Illiano G . Leptin potentiates antiproliferative action of camp elevation Via protein kinase a down-regulation in breast cancer cells. J Cell Physiol (2010) 225(3):801–9. doi: 10.1002/jcp.22288 Liang X Wang S Wang X Zhang L Zhao H Zhang L . Leptin promotes the growth of breast cancer by upregulating the Wnt/Beta-catenin pathway. Exp Ther Med (2018) 16(2):767–71. doi: 10.3892/etm.2018.6212 Hosney M Sabet S El-Shinawi M Gaafar KM Mohamed MM . Leptin is overexpressed in the tumor microenvironment of obese patients with estrogen receptor positive breast cancer. Exp Ther Med (2017) 13(5):2235–46. doi: 10.3892/etm.2017.4291 Kim HG Jin SW Kim YA Khanal T Lee GH Kim SJ . Leptin induces creb-dependent aromatase activation through cox-2 expression in breast cancer cells. Food Chem Toxicol (2017) 106(Pt A):232–41. doi: 10.1016/j.fct.2017.05.058 Zahid H Subbaramaiah K Iyengar NM Zhou XK Chen IC Bhardwaj P . Leptin regulation of the P53-Hif1alpha/Pkm2-Aromatase axis in breast adipose stromal cells: A novel mechanism for the obesity-breast cancer link. Int J Obes (Lond) (2018) 42(4):711–20. doi: 10.1038/ijo.2017.273 Morad V Abrahamsson A Dabrosin C . Estradiol affects extracellular Leptin:Adiponectin ratio in human breast tissue in vivo. J Clin Endocrinol Metab (2014) 99(9):3460–7. doi: 10.1210/jc.2014-1129 Mauro L Naimo GD Gelsomino L Malivindi R Bruno L Pellegrino M . Uncoupling effects of estrogen receptor alpha on Lkb1/Ampk interaction upon adiponectin exposure in breast cancer. FASEB J (2018) 32(8):4343–55. doi: 10.1096/fj.201701315R Mauro L Pellegrino M Giordano F Ricchio E Rizza P De Amicis F . Estrogen receptor-alpha drives adiponectin effects on cyclin D1 expression in breast cancer cells. FASEB J (2015) 29(5):2150–60. doi: 10.1096/fj.14-262808 Huang J Lok V Ngai CH Zhang L Yuan J Lao XQ . Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterology (2021) 160(3):744–54. doi: 10.1053/j.gastro.2020.10.007 Carreras-Torres R Johansson M Gaborieau V Haycock PC Wade KH Relton CL . The role of obesity, type 2 diabetes, and metabolic factors in pancreatic cancer: A mendelian randomization study. J Natl Cancer Inst (2017) 109(9):djx012. doi: 10.1093/jnci/djx012 Valsecchi ME McDonald M Brody JR Hyslop T Freydin B Yeo CJ . Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer (2012) 118(14):3484–93. doi: 10.1002/cncr.26661 Du C da Silva A Morales-Oyarvide V Dias Costa A Kozak MM Dunne RF . Insulin-like growth factor-1 receptor expression and disease recurrence and survival in patients with resected pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2020) 29(8):1586–95. doi: 10.1158/1055-9965.EPI-19-1315 Chang ML . Fatty pancreas-centered metabolic basis of pancreatic adenocarcinoma: From obesity, diabetes and pancreatitis to oncogenesis. Biomedicines (2022) 10(3):692. doi: 10.3390/biomedicines10030692 Deng J Guo Y Du J Gu J Kong L Tao B . The intricate crosstalk between insulin and pancreatic ductal adenocarcinoma: A review from clinical to molecular. Front Cell Dev Biol (2022) 10:844028. doi: 10.3389/fcell.2022.844028 Tian X Hao K Qin C Xie K Xie X Yang Y . Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer. Dig Dis Sci (2013) 58(9):2705–12. doi: 10.1007/s10620-013-2673-2 Mann KM Ying H Juan J Jenkins NA Copeland NG . Kras-related proteins in pancreatic cancer. Pharmacol Ther (2016) 168:29–42. doi: 10.1016/j.pharmthera.2016.09.003 Appleman VA Ahronian LG Cai J Klimstra DS Lewis BC . Kras(G12d)- and Braf(V600e)-induced transformation of murine pancreatic epithelial cells requires Mek/Erk-stimulated Igf1r signaling. Mol Cancer Res (2012) 10(9):1228–39. doi: 10.1158/1541-7786.MCR-12-0340-T Jiang J Fan Y Zhang W Shen Y Liu T Yao M . Adiponectin suppresses human pancreatic cancer growth through attenuating the beta-catenin signaling pathway. Int J Biol Sci (2019) 15(2):253–64. doi: 10.7150/ijbs.27420 Harbuzariu A Rampoldi A Daley-Brown DS Candelaria P Harmon TL Lipsey CC . Leptin-notch signaling axis is involved in pancreatic cancer progression. Oncotarget (2017) 8(5):7740–52. doi: 10.18632/oncotarget.13946 Takenaga K Akimoto M Koshikawa N Nagase H . Obesity reduces the anticancer effect of adiporon against orthotopic pancreatic cancer in diet-induced obese mice. Sci Rep (2021) 11(1):2923. doi: 10.1038/s41598-021-82617-2 Akimoto M Maruyama R Kawabata Y Tajima Y Takenaga K . Antidiabetic adiponectin receptor agonist adiporon suppresses tumour growth of pancreatic cancer by inducing Ripk1/Erk-dependent necroptosis. Cell Death Dis (2018) 9(8):804. doi: 10.1038/s41419-018-0851-z Mendonsa AM Chalfant MC Gorden LD VanSaun MN . Modulation of the leptin receptor mediates tumor growth and migration of pancreatic cancer cells. PloS One (2015) 10(4):e0126686. doi: 10.1371/journal.pone.0126686 Messaggio F Mendonsa AM Castellanos J Nagathihalli NS Gorden L Merchant NB . Adiponectin receptor agonists inhibit leptin induced Pstat3 and in vivo pancreatic tumor growth. Oncotarget (2017) 8(49):85378–91. doi: 10.18632/oncotarget.19905 Ragone A Salzillo A Spina A Naviglio S Sapio L . Integrating gemcitabine-based therapy with adiporon enhances growth inhibition in human pdac cell lines. Front Pharmacol (2022) 13:837503. doi: 10.3389/fphar.2022.837503 Zamorano AS Hagemann AR Morrison L Lee JA Liao LM Brinton LA . Pre-diagnosis body mass index, physical activity and ovarian cancer mortality. Gynecol Oncol (2019) 155(1):105–11. doi: 10.1016/j.ygyno.2019.07.025 Iyoshi S Sumi A Yoshihara M Kitami K Mogi K Uno K . Obesity contributes to the stealth peritoneal dissemination of ovarian cancer: A multi-institutional retrospective cohort study. Obes (Silver Spring) (2022) 30(8):1599–607. doi: 10.1002/oby.23497 Ignacio RMC Lee ES Wilson AJ Beeghly-Fadiel A Whalen MM Son DS . Obesity-induced peritoneal dissemination of ovarian cancer and dominant recruitment of macrophages in ascites. Immune Netw (2018) 18(6):e47. doi: 10.4110/in.2018.18.e47 Kato S Abarzua-Catalan L Trigo C Delpiano A Sanhueza C Garcia K . Leptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: An explanation for poor outcomes in obese women. Oncotarget (2015) 6(25):21100–19. doi: 10.18632/oncotarget.4228 Alsina-Sanchis E Figueras A Lahiguera A Vidal A Casanovas O Graupera M . The tgfbeta pathway stimulates ovarian cancer cell proliferation by increasing Igf1r levels. Int J Cancer (2016) 139(8):1894–903. doi: 10.1002/ijc.30233 Kokts-Porietis RL Elmrayed S Brenner DR Friedenreich CM . Obesity and mortality among endometrial cancer survivors: A systematic review and meta-analysis. Obes Rev (2021) 22(12):e13337. doi: 10.1111/obr.13337 Merritt MA Strickler HD Einstein MH Yang HP Sherman ME Wentzensen N . Insulin/Igf and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. Cancer Causes Control (2016) 27(6):737–48. doi: 10.1007/s10552-016-0751-4 Hewitt SC Winuthayanon W Lierz SL Hamilton KJ Donoghue LJ Ramsey JT . Role of eralpha in mediating female uterine transcriptional responses to Igf1. Endocrinology (2017) 158(8):2427–35. doi: 10.1210/en.2017-00349 Majchrzak-Baczmanska D Malinowski A . Does igf-1 play a role in the biology of endometrial cancer? Ginekol Pol (2016) 87(8):598–604. doi: 10.5603/GP.2016.0052 Kitahara CM Pfeiffer RM Sosa JA Shiels MS . Impact of overweight and obesity on us papillary thyroid cancer incidence trends (1995-2015). J Natl Cancer Inst (2020) 112(8):810–7. doi: 10.1093/jnci/djz202 Franchini F Palatucci G Colao A Ungaro P Macchia PE Nettore IC . Obesity and thyroid cancer risk: An update. Int J Environ Res Public Health (2022) 19(3):1116. doi: 10.3390/ijerph19031116 Qian F Huo D . Circulating insulin-like growth factor-1 and risk of total and 19 site-specific cancers: Cohort study analyses from the uk biobank. Cancer Epidemiol Biomarkers Prev (2020) 29(11):2332–42. doi: 10.1158/1055-9965.EPI-20-0743 Yang L Tan Z Li Y Zhang X Wu Y Xu B . Insulin-like growth factor 1 promotes proliferation and invasion of papillary thyroid cancer through the Stat3 pathway. J Clin Lab Anal (2020) 34(12):e23531. doi: 10.1002/jcla.23531 Manzella L Massimino M Stella S Tirro E Pennisi MS Martorana F . Activation of the igf axis in thyroid cancer: Implications for tumorigenesis and treatment. Int J Mol Sci (2019) 20(13):3258. doi: 10.3390/ijms20133258 Zhang T Shen H Dong W Qu X Liu Q Du J . Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to igf-1 receptor, in esophageal carcinoma. Sci Rep (2014) 4:6855. doi: 10.1038/srep06855 Calzone FJ Cajulis E Chung YA Tsai MM Mitchell P Lu J . Epitope-specific mechanisms of Igf1r inhibition by ganitumab. PloS One (2013) 8(2):e55135. doi: 10.1371/journal.pone.0055135 Fuentes-Baile M Ventero MP Encinar JA Garcia-Morales P Poveda-Deltell M Perez-Valenciano E . Differential effects of igf-1r small molecule tyrosine kinase inhibitors bms-754807 and osi-906 on human cancer cell lines. Cancers (Basel) (2020) 12(12):3717. doi: 10.3390/cancers12123717 Girnita A Girnita L del Prete F Bartolazzi A Larsson O Axelson M . Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res (2004) 64(1):236–42. doi: 10.1158/0008-5472.can-03-2522 Friedbichler K Hofmann MH Kroez M Ostermann E Lamche HR Koessl C . Pharmacodynamic and antineoplastic activity of bi 836845, a fully human igf ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin. Mol Cancer Ther (2014) 13(2):399–409. doi: 10.1158/1535-7163.MCT-13-0598 Gradishar WJ Yardley DA Layman R Sparano JA Chuang E Northfelt DW . Clinical and translational results of a phase ii, randomized trial of an anti-Igf-1r (Cixutumumab) in women with breast cancer that progressed on endocrine therapy. Clin Cancer Res (2016) 22(2):301–9. doi: 10.1158/1078-0432.CCR-15-0588 Abou-Alfa GK Capanu M O'Reilly EM Ma J Chou JF Gansukh B . A phase ii study of cixutumumab (Imc-A12, Nsc742460) in advanced hepatocellular carcinoma. J Hepatol (2014) 60(2):319–24. doi: 10.1016/j.jhep.2013.09.008 Weigel B Malempati S Reid JM Voss SD Cho SY Chen HX . Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the children's oncology group. Pediatr Blood Cancer (2014) 61(3):452–6. doi: 10.1002/pbc.24605 Rajan A Carter CA Berman A Cao L Kelly RJ Thomas A . Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: A multicentre, open-label, phase 2 trial. Lancet Oncol (2014) 15(2):191–200. doi: 10.1016/s1470-2045(13)70596-5 Schoffski P Adkins D Blay JY Gil T Elias AD Rutkowski P . An open-label, phase 2 study evaluating the efficacy and safety of the anti-Igf-1r antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer (2013) 49(15):3219–28. doi: 10.1016/j.ejca.2013.06.010 Juergens H Daw NC Geoerger B Ferrari S Villarroel M Aerts I . Preliminary efficacy of the anti-Insulin-Like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol (2011) 29(34):4534–40. doi: 10.1200/JCO.2010.33.0670 Reidy-Lagunes DL Vakiani E Segal MF Hollywood EM Tang LH Solit DB . A phase 2 study of the insulin-like growth factor-1 receptor inhibitor mk-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer (2012) 118(19):4795–800. doi: 10.1002/cncr.27459 Bergqvist M Holgersson G Bondarenko I Grechanaya E Maximovich A Andor G . Phase ii randomized study of the igf-1r pathway modulator Axl1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer. Acta Oncol (2017) 56(3):441–7. doi: 10.1080/0284186X.2016.1253866 Fassnacht M Berruti A Baudin E Demeure MJ Gilbert J Haak H . Linsitinib (Osi-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study. Lancet Oncol (2015) 16(4):426–35. doi: 10.1016/s1470-2045(15)70081-1 Barata P Cooney M Tyler A Wright J Dreicer R Garcia JA . A phase 2 study of osi-906 (Linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (Non-opioid requiring) metastatic castrate resistant prostate cancer (Crpc). Invest New Drugs (2018) 36(3):451–7. doi: 10.1007/s10637-018-0574-0 de Bono J Lin CC Chen LT Corral J Michalarea V Rihawi K . Two first-in-Human studies of xentuzumab, a humanised insulin-like growth factor (Igf)-neutralising antibody, in patients with advanced solid tumours. Br J Cancer (2020) 122(9):1324–32. doi: 10.1038/s41416-020-0774-1 Doi T Kuboki Y Naito Y Ishida M Tanaka T Takeuchi Y . A phase 1 trial of xentuzumab, an igf-neutralizing antibody, in Japanese patients with advanced solid tumors. Cancer Sci (2022) 113(3):1010–7. doi: 10.1111/cas.15231 Tsui J Qi S Perrino S Leibovitch M Brodt P . Identification of a resistance mechanism to igf-ir targeting in human triple negative mda-Mb-231 breast cancer cells. Biomolecules (2021) 11(4):527. doi: 10.3390/biom11040527 Iida M Tsuboi K Niwa T Ishida T Hayashi SI . Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer. Breast Cancer (2019) 26(3):272–81. doi: 10.1007/s12282-018-0922-0 Ma G Tan C Shan Y Shao N Wang F Dimitrov DS . An insulin growth factor-I/Ii-Neutralizing monoclonal antibody in combination with epidermal growth factor receptor inhibitors potently inhibits tumor cell growth. J Cancer (2022) 13(6):1830–6. doi: 10.7150/jca.69064 Kruger DT Alexi X Opdam M Schuurman K Voorwerk L Sanders J . Igf-1r pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in er-positive breast cancer. Int J Cancer (2020) 146(8):2348–59. doi: 10.1002/ijc.32668 De Martino MC van Koetsveld PM Feelders RA de Herder WW Dogan F Janssen J . Igf and mtor pathway expression and in vitro effects of linsitinib and mtor inhibitors in adrenocortical cancer. Endocrine (2019) 64(3):673–84. doi: 10.1007/s12020-019-01869-1 Di Cosimo S Sathyanarayanan S Bendell JC Cervantes A Stein MN Brana I . Combination of the mtor inhibitor ridaforolimus and the anti-Igf1r monoclonal antibody dalotuzumab: Preclinical characterization and phase I clinical trial. Clin Cancer Res (2015) 21(1):49–59. doi: 10.1158/1078-0432.CCR-14-0940 Ireland L Santos A Campbell F Figueiredo C Hammond D Ellies LG . Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer. Oncogene (2018) 37(15):2022–36. doi: 10.1038/s41388-017-0115-x Chen L Zhu Z Gao W Jiang Q Yu J Fu C . Systemic analysis of different colorectal cancer cell lines and tcga datasets identified igf-1r/Egfr-Ppar-Caspase axis as important indicator for radiotherapy sensitivity. Gene (2017) 627:484–90. doi: 10.1016/j.gene.2017.07.003 Zong R Chen X Feng J Xu S . Igf-1r depletion sensitizes colon cancer cell lines to radiotherapy. Cancer biomark (2021) 32(2):199–206. doi: 10.3233/CBM-210016